Please select the option that best describes you:
When do you consider using high dose IL-2 in patients with mRCC?
Are there any patient and/or pathologic features that would lend you to considering IL-2 over other approved I/O or TKI therapies?
Answer from: Medical Oncologist at Academic Institution
There were patients in the earlier Ipi/nivo phase 2 experience who were IL-2 failures and responded to Ipi/nivo, raising the hypothesis that the mechanism of response is not entirely overlapping. Thus, I believe HD IL-2 could still have a role even with modern combos, but will be used sparingly give...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
The data for IL-2 has always been based on a carefully selected population - patients largely had lung only metastases, good performance status and other favorable features that truly skewed the data. Regimens such as nivolumab/ipilimumab and more recently axitinib/pembrolizumab certainly provide a ...